Reconvened SAGE Working Group on Dengue Vaccines and Vaccination (December 2017 to October 2018)

The reconvened Dengue Working Group is asked to review new data on the long-term follow-up of dengue vaccine recipients. This includes data generated by further laboratory testing and analysis related to the long-term safety and efficacy of CYD-TDV Phase 3 trial participants. In particular, the group is asked to review the differential performance of the CYD-TDV vaccine (also known as Dengvaxia®) in subjects seronegative versus seropositive at the time of vaccination. The group is asked to advise on a revision of WHO’s current vaccine recommendations as published in July 2016. The review at SAGE is tentatively scheduled for April 2018. This will lead to the publication of an amended WHO position paper on the use of a dengue vaccine, which will replace the interim recommendation issued by WHO on 22 Dec 2017 (WHO interim position on the use of Dengvaxia®)